160 related articles for article (PubMed ID: 35042700)
1. Linezolid Metabolism Is Catalyzed by Cytochrome P450 2J2, 4F2, and 1B1.
Obach RS
Drug Metab Dispos; 2022 Apr; 50(4):413-421. PubMed ID: 35042700
[TBL] [Abstract][Full Text] [Related]
2. Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.
Zhao T; Chen Y; Wang D; Wang L; Dong P; Zhao S; Wang C; Meng Q; Sun H; Liu K; Wu J
Cardiovasc Drugs Ther; 2022 Feb; 36(1):121-129. PubMed ID: 33411110
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
4. CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.
Wu Z; Lee D; Joo J; Shin JH; Kang W; Oh S; Lee DY; Lee SJ; Yea SS; Lee HS; Lee T; Liu KH
Antimicrob Agents Chemother; 2013 Nov; 57(11):5448-56. PubMed ID: 23959307
[TBL] [Abstract][Full Text] [Related]
5. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
6. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
[TBL] [Abstract][Full Text] [Related]
7. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.
Phuc NM; Wu Z; O Y; Lee JH; Oh S; Song GY; Liu KH
Drug Metab Dispos; 2017 Jul; 45(7):765-769. PubMed ID: 28461575
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.
Liu KH; Kim MG; Lee DJ; Yoon YJ; Kim MJ; Shon JH; Choi CS; Choi YK; Desta Z; Shin JG
Drug Metab Dispos; 2006 Nov; 34(11):1793-7. PubMed ID: 16896065
[TBL] [Abstract][Full Text] [Related]
9. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.
Hiratsuka M; Hinai Y; Sasaki T; Konno Y; Imagawa K; Ishikawa M; Mizugaki M
Drug Metab Dispos; 2007 Oct; 35(10):1730-2. PubMed ID: 17646278
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel substrates for human cytochrome P450 2J2.
Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity.
Šadibolová M; Juvonen RO; Auriola S; Boušová I
Arch Toxicol; 2022 Mar; 96(3):793-808. PubMed ID: 34989853
[TBL] [Abstract][Full Text] [Related]
13. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Lee CA; Jones JP; Katayama J; Kaspera R; Jiang Y; Freiwald S; Smith E; Walker GS; Totah RA
Drug Metab Dispos; 2012 May; 40(5):943-51. PubMed ID: 22328583
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Jeong HU; Lee HS
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468305
[TBL] [Abstract][Full Text] [Related]
15. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
16. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
[TBL] [Abstract][Full Text] [Related]
18. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.
Crewe HK; Notley LM; Wunsch RM; Lennard MS; Gillam EM
Drug Metab Dispos; 2002 Aug; 30(8):869-74. PubMed ID: 12124303
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
